Haemostatic variables in arterial hypertension. 1995

A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
Department of Internal Medicine, Messina University, Italy.

In 22 untreated patients with uncomplicated essential hypertension and in 10 normotensive subjects the plasma levels of thrombomodulin (TM), beta-thromboglobulin (beta-TG), D-dimer (DD), tissue-type plasminogen activator (t-PA) and plasminogen activator-inhibitor (PAI-1) were evaluated. The observed values show no significant difference in plasma TM, plasma and urine beta-TG concentration and plasma DD among hypertensive patients and controls. On the other hand, the levels of t-PA and PAI-1 in hypertensive patients were significantly higher than the values detected in normotensive control subjects. These data seem to indicate that, at initial stages of essential hypertension, the t-PA and PAI-1 levels increase.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D010979 Platelet Function Tests Laboratory examination used to monitor and evaluate platelet function in a patient's blood. Function Test, Platelet,Function Tests, Platelet,Platelet Function Test,Test, Platelet Function,Tests, Platelet Function
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D005260 Female Females
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation

Related Publications

A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
July 1980, Thrombosis and haemostasis,
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
January 1983, Lancet (London, England),
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
November 2000, Archives des maladies du coeur et des vaisseaux,
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
January 1979, Thrombosis research,
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
March 1994, International journal of cardiology,
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
January 1980, Thrombosis research,
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
September 1977, British medical bulletin,
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
November 2019, International journal of cardiology,
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
October 1986, European heart journal,
A Trifiletti, and N Barbera, and M A Pizzoleo, and A Lasco, and S Lucifora, and G Leone, and S Soraci, and M Pedullà, and N Frisina
January 1996, Journal of inherited metabolic disease,
Copied contents to your clipboard!